These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 36529238)

  • 1. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
    Kou L; Xie X; Chen X; Li B; Li J; Li Y
    Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
    Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
    Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L
    Elife; 2024 Aug; 13():. PubMed ID: 39146202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
    Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
    Yan ZJ; Yu CT; Chen L; Wang HY
    Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
    Sharma R; Motedayen Aval L
    Front Immunol; 2021; 12():652007. PubMed ID: 33790915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).
    Bicer F; Kure C; Ozluk AA; El-Rayes BF; Akce M
    Curr Oncol; 2023 Nov; 30(11):9789-9812. PubMed ID: 37999131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.